Abstract
AbstractThis article explores the significance of lived experience to understandings of severity in the genomic age. It draws upon data from structured interviews with 21 people living with monogenic conditions in England. The article argues that while lived experiences are subjective, participants consider the severity of disease by the impact a condition has on a person’s quality of life and mental health; both of these interplays are influenced by social, economic, and environmental factors. The three factors and considerations to the impact of living with disease on mental health are generally absent from current frameworks designed to assess severity for clinical applications of genomic technologies such as preimplantation genetic testing (PGT). This article describes ways in which such factors impact the quality of life and the mental health of people living with genetic conditions. It also indicates what lived experiences, which illustrate the impact of these factors, have to offer policy-makers when they are assessing the concept of severity or seriousness of genetic conditions for applications of existing and potential genomic technologies in the genomic age.
Funder
RCUK | Economic and Social Research Council
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Shendure J, Findlay GM, Snyder MW. Genomic medicine–progress, pitfalls, and promise. Cell. 2019;177:45–57.
2. Salit M, Woodcock J. MAQC and the era of genomic medicine. Nat Biotechnol. 2021;39:1066–7.
3. International Commission on the Clinical Use of Human Germline Genome Editing, The Royal Society, National Academy of Medicine, National Academy of Sciences. In: Heritable Human Genome Editing. Washington (DC): National Academies Press (US); 2020. http://www.ncbi.nlm.nih.gov/books/NBK561519/.
4. Wertz DC, Knoppers BM. Serious genetic disorders: can or should they be defined? Am J Med Genet. 2002;108:29–35.
5. Kleiderman E, Ravitsky V, Knoppers BM. The ‘Serious’ factor in germline modification. J Med Ethics. 2019;45:508–13.